Tag: antipsychotic
FDA to Review âDigital Pillâ to Monitor Patients on Antipsychotic
Last Thursday, the FDA agreed to review a âdigital pill,â combining a sensor with the antipsychotic Abilify, in order to track patientsâ compliance with drug treatment. Patients taking the tracker pill would also wear a patch, which would receive information and relay it to a mobile device, according to a brief report by BioPharmaDIVE.
My Father-in-law on Risperdal â A Case Study Gets Personal
Risperdal is increasingly used in nursing homes for âagitation,â especially on those suffering from some form of dementia, even when no hallucinations or delusions are observed. Risperdal has quite a long list of side effects including heart problems, metabolic difficulties, diabetes, involuntary movements, agitation, flat affect and sedation. Risperdal has earned a âblack box" warning that its use in those with Alzheimer's increases the risk of earlier death. Yet its use in Alzheimer's patients in nursing homes is extremely common.
On Relaxing Off-Label Meds:Â Do the Opposite. Especially for Children. Especially Antipsychotics
The US Food and Drug Administration has announced that there will soon be a public meeting to explore providing drug companies with greater flexibility in promoting off-label indications to doctors. When it comes to prescribing medications to children, and particularly psychiatric medications, this is a bad idea. I write both as a former consultant to the pharmaceutical industry, and as a father who lost a son to the toxic effects of antipsychotics prescribed off-label.
The Once and Future Abilify: Depot Injections for Everyone?
This column is partly a report on the marketing of Abilify, the atypical antipsychotic that has become Americaâs best-selling drug.  Itâs also an appeal for advice and feedback from the RxISK and Mad in America communities, and a call for some brainstorming about strategy. The plans laid out by drugmakers Otsuka and Lundbeck for Abilifyâs future, and the cooperation theyâre getting from leading universities, are alarming enough to me that reporting on them seems inadequate. We need action, although Iâm not sure exactly what kind.
Psych Meds Put 49 Million Americans at Risk for Cancer
With 1 in 5 Americans taking a psychiatric medication, most of whom, long term, we should probably start to learn a bit more about them. In fact, it would have been in the service of true informed consent to have investigated long-term risks before the deluge of these meds seized our population over the past thirty years.